Published in Medical Letter on the CDC and FDA, May 30th, 2004
Under the terms of the agreement, Ortec will supply ESI with human skin cells generated from cell lines developed and manufactured by Ortec for use in its tissue engineered product, OrCel. The cells to be provided have undergone extensive testing for viruses in accordance with current U.S. Food and Drug Administration (FDA) guidelines and are expected to be used by ESI in research and development and in commercialization of their stem-cell products.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.